Nathan Denlinger
Nathan Denlinger
Explore linked clinical trials.2 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Lymphodepletion With Low Dose Total Body Irradiation Before Standard of Care Tisagenlecleucel for the Treatment of Relapsed and Recurrent Large B-cell Lymphoma | B-cell neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, diffuse large B-cell lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 1 | 2026-10-09 | NCT07676877 | |
| CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma | B-Cell Non-Hodgkin Lymphoma-Recurrent; B-Cell Non-Hodgkin Lymphoma-Refractory; Diffuse Large B-Cell Lymphoma-Recurrent; Diffuse Large B-Cell Lymphoma-Refractory; Follicular Lymphoma-Recurrent; Follicular Lymphoma-Refractory; High Grade B-Cell Lymphoma-Recurrent; High Grade B-Cell Lymphoma-Refractory; Primary Mediastinal Large B-Cell Lymphoma-Recurrent; Primary Mediastinal Large B-Cell Lymphoma-Refractory; Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma-Recurrent; Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma-Refractory | Recruiting | Phase 1 | 2026-02-27 | NCT06209619 |